Opening Address & Keynote Presentation: Navigating the Drug Development Pathway in Immunotherapies
29 Oct 2024
Immunogenicity
,
Translational Immunology
,
Clinical Development
,
Immune Regulation
)
Drug development in immunotherapies is rapidly evolving with multiple new guidances from the FDA and increasing complexity in asset types. We will review the regulatory landscape and how to partner with the right team to manage the path through early-stage development. Key topics will include project optimus, best practices and working with CROs as well as important considerations for development of immunotherapies.
